MEDVi

About MEDVi

MEDVi, LLC is a telehealth company specializing in physician-supervised weight management and metabolic health. The company was founded by Matthew Gallagher, who was later joined by his brother, Elliot. Leveraging AI tools, Matthew Gallagher launched the startup in two months with an initial investment of $20,000. In its first full year of business in 2025, MEDVi generated $401 million in sales with 250,000 customers. The company is on track to reach $1.8 billion in sales in 2026.

Headquartered in Newark, Delaware, MEDVi operates as a digital platform that connects patients with licensed U.S. healthcare providers for virtual consultations and treatment plans. The business model is a direct-to-consumer, cash-pay subscription service, meaning it does not accept insurance. Monthly membership fees cover medical consultations, prescription medications, shipping, and ongoing support. The platform is designed to provide a more accessible and affordable alternative to traditional clinic-based weight loss programs.

MEDVi's core offering is its online weight loss program, which provides access to GLP-1 (glucagon-like peptide-1) agonist medications, such as compounded semaglutide and tirzepatide. These medications, available in injectable or oral tablet form, work by regulating appetite and slowing digestion. After an online health evaluation, a licensed physician reviews the patient's information to determine if a GLP-1 prescription is appropriate. If approved, the compounded medications are prepared by certified U.S. compounding pharmacies and shipped directly to the patient. The program includes 24/7 messaging support and unlimited appointments with providers. Beyond medication, MEDVi also offers personal care coaching, nutrition support from registered dietitians, and a meal delivery service called MEDVi Meals, designed to complement the GLP-1 treatments.